These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16297390)

  • 21. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
    Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
    AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1.
    Watson DC; Farley JJ
    Pediatr Infect Dis J; 1999 Aug; 18(8):682-9. PubMed ID: 10462336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy.
    Mandal A; Mukherjee A; Lakshmy R; Kabra SK; Lodha R
    Indian J Pediatr; 2016 Mar; 83(3):226-31. PubMed ID: 26334860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV, HAART, and hyperlipidemia: balancing the effects.
    Sherer R
    J Acquir Immune Defic Syndr; 2003 Oct; 34 Suppl 2():S123-9. PubMed ID: 14703941
    [No Abstract]   [Full Text] [Related]  

  • 27. Care of Patients With HIV Infection: Antiretroviral Drug Regimens.
    Bolduc P; Roder N; Colgate E; Cheeseman SH
    FP Essent; 2016 Apr; 443():23-30. PubMed ID: 27092564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction.
    Francisci D; Giannini S; Baldelli F; Leone M; Belfiori B; Guglielmini G; Malincarne L; Gresele P
    AIDS; 2009 Mar; 23(5):589-96. PubMed ID: 19177019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. The Master Group.
    Clerici M; Seminari E; Suter F; Castelli F; Pan A; Biasin M; Colombo F; Trabattoni D; Maggiolo F; Carosi G; Maserati R
    AIDS; 2000 Jan; 14(2):109-16. PubMed ID: 10708280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tuberculosis and HIV co-infection: a practical therapeutic approach.
    Breen RA; Swaden L; Ballinger J; Lipman MC
    Drugs; 2006; 66(18):2299-308. PubMed ID: 17181373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Class of antiretroviral drugs and the risk of myocardial infarction.
    ; Friis-Møller N; Reiss P; Sabin CA; Weber R; Monforte Ad; El-Sadr W; Thiébaut R; De Wit S; Kirk O; Fontas E; Law MG; Phillips A; Lundgren JD
    N Engl J Med; 2007 Apr; 356(17):1723-35. PubMed ID: 17460226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
    AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus non-protease inhibitor containing HAART regimens.
    Visnegarwala F; Darcourt J; Sajja P; Menon V; Ong O; Maldonado M; White AC
    J Acquir Immune Defic Syndr; 2003 Aug; 33(5):653-5. PubMed ID: 12902814
    [No Abstract]   [Full Text] [Related]  

  • 35. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.
    DeSimone JA; Pomerantz RJ; Babinchak TJ
    Ann Intern Med; 2000 Sep; 133(6):447-54. PubMed ID: 10975963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe dyslipidemia and immune activation in HIV patients with dysglycemia.
    Jin C; Ji S; Xie T; Höxtermann S; Fuchs W; Lu X; Wu H; Cheng L; Skaletz-Rorowski A; Brockmeyer NH; Wu N
    HIV Clin Trials; 2016 Sep; 17(5):189-96. PubMed ID: 27409415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.
    Spector SA; Hsia K; Yong FH; Cabral S; Fenton T; Fletcher CV; McNamara J; Mofenson LM; Starr SE
    J Infect Dis; 2000 Dec; 182(6):1769-73. PubMed ID: 11069252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection.
    Klein MB; Willemot P; Murphy T; Lalonde RG
    AIDS; 2004 Sep; 18(14):1895-904. PubMed ID: 15353975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?
    Bradbury RA; Samaras K
    Diabetes Obes Metab; 2008 Jun; 10(6):441-50. PubMed ID: 17825081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
    Saitoh A; Fenton T; Alvero C; Fletcher CV; Spector SA
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4236-42. PubMed ID: 17893156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.